Abstract
Background and aim
The most effective way to control severity and mortality rate of the novel coronavirus disease (COVID-19) is through sensitive diagnostic approaches and an appropriate treatment protocol. We aimed to identify the effect of adding corticosteroid and Tocilizumab to a standard treatment protocol in treating COVID-19 patients with chronic disease through hematological and lab biomarkers.
Materials and methods
This study was performed retrospectively on 68 COVID-19 patients with chronic disease who were treated by different therapeutic protocols. The patients were categorized into four groups: control group represented the patients’ lab results at admission before treatment protocols were applied; group 1 included patients treated with anticoagulants, Hydroxychloroquine, and antibiotics; group 2 comprised patients treated with Dexamethasone; and group 3 included patients treated with Dexamethasone and Tocilizumab.
Results
The WBC and neutrophil counts were increased significantly in group 3 upon the treatment when they were compared with patients in group 1 (p = 0.004 and p = 0.001, respectively). The comparison of C-reactive Protein (CRP) level at admission was higher in group 3 than in group 1 with p = 0.030. After 10 days of treatment, CRP level was decreased in all groups, but in group 3 it was statistically significant (p = 0.002).
Conclusion
The study paves the way into the effectiveness of combining Dexamethasone with Tocilizumab in treatment COVID-19 patients with chronic diseases.
【저자키워드】 severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019, C-reactive protein, complete blood count, COVID-19coronavirus disease 2019, SARS-CoV-2severe acute respiratory syndrome coronavirus 2, CRPC-reactive protein, ARDSsevere acute respiratory distress syndrome, severe acute respiratory distress syndrome, CBCcomplete blood count, 【초록키워드】 Corticosteroid, COVID-19, Treatment, Biomarkers, protocol, severity, diagnostic, CRP, novel coronavirus disease, chronic disease, therapeutic, Patient, Treatment protocol, Effectiveness, WBC, mortality rate, Admission, Anticoagulants, protocols, COVID-19 patient, Chronic diseases, control group, standard treatment, neutrophil count, hematological, material, CRP level, lab, effective, Result, identify, approach, significantly, was performed, treated, groups, statistically significant, patients treated, treating COVID-19 patient, 【제목키워드】 Dexamethasone, Tocilizumab, chronic disease, Impact, COVID-19 patient, hematological parameter,